References
- BuxtonILBenetLZPharmacokinetics: The Dynamics of Drug Absorption, Distribution, Metabolism, and EliminationBruntonLLChabnerBAKnollmannBCGoodman & Gilman’s The Pharmacological Basis of Therapeutic12th edNew YorkMcGraw-Hill2011
- MalletLSpinewineAHuangAThe challenge of managing drug interactions in elderly peopleLancet2007370958218519117630042
- HanlonJTLindbladCIHajjarERMcCarthyTCUpdate on drug-related problems in the elderlyAm J Geriatr Pharmacother200311384315555464
- GurwitzJHFieldTSHarroldLRIncidence and preventability of adverse events among older persons in the ambulatory settingJAMA200328991107111612622580
- TangiisuranBWrightJVan der CammenTRajkumarCAdverse drug reactions in elderly: challenges in identification and improving preventative strategiesAge Ageing200938435835919420141
- SeeleyWWMillerBLDementiaLongoDLFauciASKasperDLHauserSHJamesonJLLoscalzoJHarrison’s Principles of Internal Medicine18th edNew YorkMcGraw-Hill2012
- LyketsosCGSteinbergMTschanzJTMental and behavioral disturbances in dementia: indings from the Cache County Study on Memory in AgingAm J Psychiatry2000157570871410784462
- RopackiSAJesteDVEpidemiology of and risk factors for psychosis of Alzheimer’s disease: a review of 55 studies published from 1990 to 2003Am J Psychiatry2005162112022203016263838
- LópezOLZivkovicGSmithGBeckerJTMeltzerCCDeKoskySTPsychiatric symptoms associated with cortical-subcortical dysfunction in Alzheimer’s diseaseJ Neuropsychiatry Clin Neurosci2001131566011207330
- AndersenFViitanenMHalvorsenDSStraumeBEngstadTACo-morbidity and drug treatment in Alzheimer’s disease. A cross sectional study of participants in the dementia study in northern NorwayBMC Geriatr2011115821970467
- HeunRSchoepfDPotluriRNatalwalaAAlzheimer’s disease and co-morbidity: increased prevalence and possible risk factors of excess mortality in a naturalistic 7-year follow-upEur Psychiatry2013281404821924588
- SmallGWRabinsPVBarryPPDiagnosis and treatment of Alzheimer’s disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer’s Association, and the American Geriatrics SocietyJAMA199727816136313719343469
- BraunerDJMuirJCSachsGATreating nondementia illnesses in patients with dementiaJAMA2000283243230323510866871
- O’BrienJTBurnsABAP Dementia Consensus GroupClinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for PsychopharmacologyJ Psychopharmacol2011258997101921088041
- GironMSForsellYBernstenCThorslundMWinbladBFastbomJPsychotropic drug use in elderly people with and without dementiaInt J Geriatr Psychiatry200116990090611571771
- OlinJTKatzIRMeyersBSSchneiderLSLebowitzBDProvisional diagnostic criteria for depression of Alzheimer disease: rationale and backgroundAm J Geriatr Psychiatry200210212914111925274
- SinkKMHoldenKFYaffeKPharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidenceJAMA2005293559660815687315
- GauthierSCummingsJBallardCManagement of behavioral problems in Alzheimer’s diseaseInt Psychogeriatr201022334637220096151
- SchneiderLSDagermanKInselPSEfficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trialsAm J Geriatr Psychiatry200614319121016505124
- GardetteVLapeyre-MestreMColeyNAntipsychotic use and mortality risk in community-dwelling Alzheimer’s disease patients: evidence for a role of dementia severityCurr Alzheimer Res2012991106111622950915
- VigenCLMackWJKeefeRSCognitive effects of atypical antipsychotic medications in patients with Alzheimer’s disease: outcomes from CATIE-ADAm J Psychiatry2011168883183921572163
- LeePEGillSSFreedmanMBronskillSEHillmerMPRochonPAAtypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic reviewBMJ200432974577515194601
- ParienteASanctussyDJMiremont-SalameGFactors associated with serious adverse reactions to cholinesterase inhibitors: a study of spontaneous reportingCNS Drugs2010241556320030419
- PereraGKhondokerMBroadbentMBreenGStewartRFactors associated with response to acetylcholinesterase inhibition in dementia: a cohort study from a secondary mental health care case register in LondonPLoS One2014911e10948425411838
- WangPSSchneeweissSAvornJRisk of death in elderly users of conventional vs atypical antipsychotic medicationsN Engl J Med2005353222335234116319382
- GillSSRochonPAHerrmannNAtypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort studyBMJ20053307489e445
- DouglasIJSmeethLExposure to antipsychotics and risk of stroke: self-controlled case series studyBMJ2008337a122718755769
- MaherARMaglioneMBagleySEfficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysisJAMA2011306121359136921954480
- LiuMETsaiSJChangWCPopulation-based 5-year follow-up study in Taiwan of dementia and risk of strokePLoS One201384e6177123626726
- TrifiròGVerhammeKMZiereGCaputiAPCh StrickerBHSturkenboomMCAll-cause mortality associated with atypical and typical antipsychotics in demented outpatientsPharmacoepidemiol Drug Saf200716553854417036366
- YoungAAgeing and physiological functionsPhilos Trans R Soc Lond B Biol Sci19973521363183718439460068
- MuhlbergWPlattDAge-dependent changes of the kidneys: Pharmacological implicationsGerontology199945524325310460985
- FulopTJrWorumICsongorJFórisGLeoveyABody composition in elderly people: I. Determination of body composition by multiisotope method and the elimination kinetics of these isotopes in healthy elderly subjectsGerontology19853116143972257
- McLeanAJLe CouteurDGAging biology and geriatric clinical pharmacologyPharmacol Rev200456216318415169926
- GinsbergGHattisDRussASonawaneBPharmacokinetic and pharmacodynamic factors that can affect sensitivity to neurotoxic sequelae in elderly individualsEnviron Health Perspect200511391243124916140636
- Bentue-FerrerDTributOPolardEAllainHClinically significant drug interactions with cholinesterase inhibitors: a guide for neurologistsCNS Drugs2003171394796314533945
- ZoliMMagalottiDBianchiGTotal and functional hepatic blood flow decrease in parallel with ageingAge Ageing1999281293310203201
- WynneHACopeLHMutchERawlinsMDWoodhouseKWJamesOFThe effect of age upon liver volume and apparent liver blood flow in healthy manHepatology1989922973012643548
- FliserDZeierMNowackRRitzERenal functional reserve in healthy elderly subjectsJ Am Soc Nephrol199337137113778439649
- TrifiròGSpinaEAge-related changes in pharmacodynamics: focus on drugs acting on central nervous and cardiovascular systemsCurr Drug Metab201112761162021495972
- MangoniAAJacksonSHAge-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applicationsBr J Clin Pharmacol200457161414678335
- KruseWHProblems and pitfalls in the use of benzodiazepines in the elderlyDrug Saf1990553283342222867
- SwiftCGEwenJMClarkePStevensonIHResponsiveness to oral diazepam in the elderly: relationship to total and free plasma concentrationsBr J Clin Pharmacol19852021111183929807
- ReidenbergMMLevyMWarnerHRelationship between diazepam dose, plasma level, age, and central nervous system depressionClin Pharmacol Ther1978234371374630787
- CastledenCMGeorgeCFMarcerDHallettCIncreased sensitivity to nitrazepam in old ageBr Med J1977160521012318894
- GreenblattDJDivollMHarmatzJSMacLaughlinDSShaderRIKinetics and clinical effects of flurazepam in young and elderly non-insomniacsClin Pharmacol Ther19813044754867285482
- CummingsJLAlzheimer’s diseaseN Engl J Med20043511566715229308
- ArcherHAEdisonPBrooksDJAmyloid load and cerebral atrophy in Alzheimer’s disease: an 11C-PIB positron emission tomography studyAnn Neurol200660114514716802294
- WestMJKawasCHStewartWFRudowGLTroncosoJCHippocampal neurons in pre-clinical Alzheimer’s diseaseNeurobiol Aging20042591205121215312966
- MorrisonJHHofPRLife and death of neurons in the aging brainScience199727853374124199334292
- MorrisonJHHofPRSelective vulnerability of corticocortical and hippocampal circuits in aging and Alzheimer’s diseaseProg Brain Res200213646748612143403
- HofPRBussièreTGoldGStereologic evidence for persistence of viable neurons in layer II of the entorhinal cortex and the CA1 field in Alzheimer diseaseJ Neuropathol Exp Neurol2003621556712528818
- CummingsJLBackCThe cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer’s diseaseAm J Geriatr Psychiatry199862 Suppl 16478
- MufsonEJCountsSEPerezSEGinsbergSDCholinergic system during the progression of Alzheimer’s disease: therapeutic implicationsExpert Rev Neurother20088111703171818986241
- RainaPSantaguidaPIsmailaAEffectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guidelineAnn Intern Med2008148537939718316756
- HowardRMcShaneRLindesayJDonepezil and memantine for moderate-to-severe Alzheimer’s diseaseN Engl J Med20123661089390322397651
- SpinaEScordoMGD’ArrigoCMetabolic drug interactions with new psychotropic agentsFundam Clin Pharmacol200317551753814703714
- SweeneyBPBromilowJLiver enzyme induction and inhibition: implications for anaesthesiaAnaesthesia200661215917716430569
- TiseoPJPerdomoCAFriedhoffLTConcurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple dosesBr J Clin Pharmacol199846Suppl 130349839763
- NagyCFKumarDPerdomoCAWasonSCullenEIPrattRDConcurrent administration of donepezil HCl and sertraline HCl in healthy volunteers: assessment of pharmacokinetic changes and safety following single and multiple oral dosesBr J Clin Pharmacol200458Suppl 1253315496220
- HuangFFuYA review of clinical pharmacokinetics and pharmacodynamics of galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, in healthy subjects and patientsCurr Clin Pharmacol20105211512420156150
- PiotrovskyVVan PeerAVan OsselaerNArmstrongMAerssensJGalantamine population pharmacokinetics in patients with Alzheimer’s disease: modeling and simulationsJ Clin Pharmacol200343551452312751272
- GrossbergGTStahelinHBMessinaJCAnandRVeachJLack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medicationsInt J Geriatr Psychiatry200015324224710713582
- WesemannWSonntagK-HMajJOn the pharmacodynamics and pharmacokinetics of memantineDrug Res198333811221134
- RoySDHawesEMMidhaKKInfluence of urinary pH on the disposition of methoxyphenamine and three metabolites in humansJ Pharm Sci19877664274323625484
- FreudenthalerSMeinekeISchreebKHBoakyeEGundert-RemyUGleiterCHInfluence of urine pH and urinary flow on the renal excretion of memantineBr J Clin Pharmacol19984665415469862242
- European Medicine AgencyEbixa Tablets SPC, Summary of Product CharacteristicsEuropean Medicine Agency (EMA) Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000463/WC500058763.pdfAccessed August 15, 2015
- HiemkeCPfuhlmannBInteractions and monitoring of antipsychotic drugsHandb Exp Pharmacol201221224126523129335
- CastbergISkogvollESpigsetOQuetiapine and drug interactions: evidence from a routine therapeutic drug monitoring serviceJ Clin Psychiatry200768101540154517960969
- Nickl-JockschatTPaulzenMSchneiderFGrozingerMDrug interaction can lead to undetectable serum concentrations of quetiapine in the presence of carbamazepineClin Neuropharmacol20093215519471186
- WhitehousePJPriceDLStrubleRGClarkAWCoyleJTDelonMRAlzheimer’s disease and senile dementia: loss of neurons in the basal forebrainScience19822154537123712397058341
- RoeCMAndersonMJSpivackBUse of anticholinergic medications by older adults with dementiaJ Am Geriatr Soc200250583684212028169
- American Geriatrics Society 2012 Beers Criteria Update Expert PanelAmerican Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adultsJ Am Geriatr Soc201260461663122376048
- ShepherdGKlein-SchwartzWEdwardsRDonepezil overdose: A tenfold dosing errorAnn Pharmacother199933781281510466911
- RöslerMAnandRCicin-SainAEfficacy and safety of rivastigmine in patients with Alzheimer’s disease: International randomised controlled trialBMJ1999318718463363810066203
- Corey-BloomJAnandRVeachJA randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s diseaseInt J Ger Psychopharmacol199815565
- TariotPNSolomonPRMorrisJCA 5-month, randomized, placebocontrolled trial of galantamine in ADNeurology200054122269227610881251
- CarnahanRMLundBCPerryPJChriscillesEAThe concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice?J Am Geriatr Soc200452122082208715571547
- RobinsonMRowettDLevertonAMabbottVChanges in utilisation of anticholinergic drugs after initiation of cholinesterase inhibitorsPharmacoepidemiol Drug Saf200918865966419548222
- TavassoliNSommetALapeyre-MestreMBagheriHMontrastrucJLDrug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary)Drug Saf200730111063107117973542
- MasudaYCardiac effect of cholinesterase inhibitors used in Alzheimer’s disease – from basic research to bedsideCurr Alzheimer Res20041431532115975060
- MorganrothJGrahamSHartmanRAnandRElectrocardiographic effects of rivastigmineJ Clin Pharmacol200242555856812017350
- BordierPGarrigueSBaroldSSBressollesNLanusseSClémentyJSignificance of syncope in patients with Alzheimer’s disease treated with cholinesterase inhibitorsEuropace20035542943114753643
- BordierPGarrigueSLanusseSCardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer’s diseaseCNS Drugs200620541141716696580
- KayrakMYaziciMAyhanSSKocFUlgenMSComplete atrioventricular block associated with rivastigmine therapyAm J Health Syst Pharm200865111051105318499878
- PaulisonBLéosCLPotential cardiotoxic reaction involving rivastigmine and beta-blockers: a case report and review of the literatureCardiovasc Toxicol201010430631020865460
- US Food Drug AdministrationDeaths with Antipsychotics in Elderly Patients with Behavioral DisturbancesUS Food and Drug Administration2005 Available from: http://www.cchrint.org/pdfs/US_Food_and_Drug_Administration_Warnings_on_Antipsychotic_Drugs.pdfAccessed August 15, 2015
- ParienteAFourrier-RéglatADucruetTAntipsychotic use and myocardial infarction in older patients with treated dementiaArch Intern Med2012172864865322450214
- PrattNRougheadEESalterARyanPChoice of observational study design impacts on measurement of antipsychotic risks in the elderly: a systematic reviewBMC Med Res Methodol2012127222682666
- BallardCWaiteJThe effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s diseaseCochrane Database Syst Rev20061CD00347616437455
- De DeynPPKatzIRBrodatyHLyonsBGreenspanABurnsAManagement of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidoneClin Neurol Neurosurg2005107649750815922506
- SchneiderLSTariotPNDagermanKSEffectiveness of atypical antipsychotic drugs in patients with Alzheimer’s diseaseN Engl J Med2006355151525153817035647
- HerrmannNLanctotKLDo atypical antipsychotics cause stroke?CNS Drugs20051929110315697324
- Van NoordCEijgelsheimMStrickerBHDrug- and non-drug-associated QT interval prolongationBr J Clin Pharmacol2010701162320642543
- Wenzel-SeifertKWittmannMHaenEQTc prolongation by psychotropic drugs and the risk of Torsade de PointesDtsch Arztebl In201110841687693
- BresslerRGrapefruit juice and drug interactions. Exploring mechanisms of this interaction and potential toxicity for certain drugsGeriatrics20066111121817112309
- Ingelman-SundbergMGenetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversityPharmacogenomics J20055161315492763
- ZhouSFXueCCYuXQLiCWangGClinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoringTher Drug Monit200729668771018043468